![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 24, 2006 4:50:21 PM
AP, Friday March 24, 10:03 am ET
Amylin Launches 30-Week Study of Long Acting, Extended-Release Version of Diabetes Drug Byetta
INDIANAPOLIS (AP) -- Amylin Pharmaceuticals Inc. said Friday it started a 30-week clinical study of a long-acting version of its Byetta diabetes drug.
The San Diego-based drugmaker is working with Eli Lilly & Co. and Alkermes Inc. on the study, which aims to see if using extended-release Byetta once a week is at least as effective as the already approved twice-daily treatment. Byetta initially received regulatory approval in April as an add-on treatment for Type 2 diabetes.
The three pharmaceutical firms, which have discussed the study with the Food and Drug Administration, intend to use the safety and effectiveness data as support for a new drug application.
Amylin shares rose 73 cents to $45.40 in morning trading on the Nasdaq, while Alkermes shares gained 33 cents to $24.39. Meanwhile, shares of Eli Lilly added 46 cents to $58.50 on the New York Stock Exchange.
http://biz.yahoo.com/ap/060324/amylin_study.html?.v=1
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM